Substitute	for	form	1449A/PTO

STATEMENT BY APPLICANT

	SHEE	品(OF <u>2</u>
ATTORNEY'S DKT NO.	APPLICATION N	162	
033053-025	09/972,425	5	T
APPLICANT	,	7	8
Kenneth C. Cundy, et al.		<u> </u>	0
FILING DATE	GROUP	30	1
October 5, 2001	1614		

JAN 3 0 2002

HADEM LATE	,		U.S. PATENT DOCUMENTS	8
HAUEN	U.S. Patent D	ocument		
Examiner Initials	Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication (MM-DD-YYYY)
26	5,541,348		Araya, et al.	7/30/1996
	5,462,933		Kramer, et al.	10/31/1995
	5,646,272		Kramer, et al.	7/8/1997
	5,668,126		Kramer, et al.	9/16/1997
	4,024,175		Satzinger	5/17/1977
	5,563,175		Silverman	10/8/1996
	5,684,018		Alexander	11/4/1997
	6,020,370		Horwell	2/1/2000
	6,028,214		Silverman	2/22/2000
	6,103,932		Horwell	8/15/2000
Par	6,117,906		Silverman	9/12/2000

FOREIGN PATENT DOCUMENTS

		Foreign Patent Document					
Examiner			Kind Code	_	Date of Publication	Translation	
	Initials	Number	(if known)	Country	(MM-DD-YYYY)	Yes	no
	3B	WO92/09560:		PCT	6/11/1992	<u> </u>	
	ĺ	WO93/23383		PCT	11/25/1993		
		WO97/29101		PCT	8/14/1997		
		WO97/33858		PCT	9/18/1997		
		WO97/33859		PCT	9/18/1997		
		WO98/17627		PCT	4/30/1998		
		WO99/08671		PCT			
		WO99/21824		PCT	5/6/1999		
		WO99/31057		PCT	6/24/1999		
		WO99/31074		PCT	6/24/1999		
		WO99/31075		PCT	6/24/1999		
		WO99/61424		PCT	12/2/1999		
		WO00/15611		PCT	3/23/2000		<u> </u>
	Ţ	WO00/23067		PCT	4/27/2000		
, <u> </u>		WO00/31020		PCT	6/2/2000		
		WO00/50027		PCT	8/31/2000		
	53	0 272 462B1		Europe	6/29/1998		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials

11

·V

13

14

15

حرا

O

Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(P	E	A								
11/2	3 0 30	الله علم	Baringhaus, KH.; Matter, H.; Stengelin, S.; Kran hepatic Na ⁺ / bile acid cotransporters of the rabbit. the ileal Na ⁺ / bile acid cotransporter. <i>J. Lipid Res</i>	II. A reliable	e 3D QSAR pharmacoph model for					
			Batta, et al., J. Lipid Res., 1991, 32, pp. 977-983							
4	TRADE	ł.	Bryans, J. S.; Wustrow, D. J. 3-Substituted GABA review. Med. Res. Rev. 1999, 19, pp. 149-177.	analogs with	n central nervous system activity: a					
			Bundgaard, H. in Design of Prodrugs (Bundgaard,	H. Ed.), Else	evier Science B.V., 1985 , pp. 1-92.					
			Ho, N. F. H. Utilizing bile acid carrier mechanism Ann. N. Y. Acad. Sci. 1987, 507, pp. 315-329.	s to enhance	liver and small intestine absorption.					
			Jezyk, N.; Li, C.; Stewart, B. H.; Wu, X.; Bockbra rat intestine and Caco-2 monolayers. <i>Pharm. Res.</i>		• • •					
			Kagedahl, M.; Swaan, P. W.; Redemann, C. T.; Ta the intestinal bile acid transporter for the uptake of inhibitory activity. <i>Pharm. Res.</i> 1997 , <i>14</i> , pp. 176	cholic acid						
			Kim, D.C., et al., Evaluation of bile acid transporte inhibitory peptides, J. Drug Targeting, 1993, 1, p		ng intestinal permeability of renin-					
			Kramer, W.; Wess, G.; Schubert, G.; Bickel, M.; C Baringhaus, KH.; Enhsen, A.; Glombik, H.; Mull Liver-specific drug targeting by coupling to bile ac	ner, S.; Neck	cermann, G.; Schulz, S.; Petzinger, E.					
			Kramer, W.; Wess, G.; Neckermann, G.; Schubert, S.; Baringhaus, KH.; Boger, G.; Enhsen, A.; Falk Pittius, C.; Urmann, M. Intestinal absorption of period 1994a, 269, pp. 10621-10627.	, E.; Friedric	h, M.; Glombik, H.; Hoffmann, A.;					
			Kramer, W.; Wess, G.; Enhsen, A.; Bock, K.; Falk Schulz, S.; Nickau, L.; Petzinger, E.; Turley, S.; Dreductase inhibitors. <i>Biochim. Biophys. Acta</i> 1994	ietschy, J. M	. Bile acid derived HMG-CoA					
			Kramer, W.; Stengelin, S.; Baringhaus, KH.; Enh Girbig, F.; Noll, R.; Weyland, C. Substrate specific cotransporters of the rabbit. I. Transport studies with cloned transporters. <i>J. Lipid Res.</i> 1999 , <i>40</i> , pp. 166	city of the ile	eal and hepatic Na+ / bile acid					
			Kullak-Ublick, G. A.; Beuers, U.; Paumgartner, G. Hepatobiliary transport. <i>J. Hepatology</i> 2000 , <i>32</i> (Suppl. 1), pp. 3-18							
-			Navia, M. A.; Chaturvedi, P. R. Design principles for orally bioavailable drugs. <i>Drug Discovery Today</i> 1996 , <i>1</i> , pp. 179-189							
			Petzinger, E.; Nickau, L.; Horz, J. A.; Schulz, S.; Wess, G.; Enhsen, A.; Falk, E.; Baringhaus, H.; K. Glombik, H.; Hoffmann, A.; Mullner, S.; Neckermann, G.; Kramer, W. Hepatobiliary transport of hepatic 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitors conjugated with bile acids., <i>Hepatology</i> 1995 , <i>22</i> , pp. 1801-1811.							
		,	Swaan, P. W.; Szoka, F. C.; Oie, S. Use of the intedering delivery. Adv. Drug Delivery Rev. 1996, 20,		epatic bile acid transporters for					
	31	В	Tsjui, A.; Tamai, I. Carrier-mediated intestinal tra -977.	nsport of dru	gs. Pharm. Res. 1996, 13, pp. 963					
	Examir Signat		Poodin	Date Considered	4/30703					

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

SHEET 1 OF 1

Substitute for form 1449A/PTO

ATTORNEY'S DKT NO. O33053-025 09/972,425

APPLICATION NO. O9/972,425

APPLICANT Kenneth C. Cundy, et al.

FILING DATE October 5, 2001 1614

WE TRADEN **U.S. PATENT DOCUMENTS** U.S. Patent Document Kind Code Name of Patentee or Applicant **Date of Publication** Examiner Number (MM-DD-YYYY) Initials (if known) of Cited Document 1313 3,326,758 6/20/67 Irmscher et al. Firestone 4,560,512 12/24/85 书马 6,143,738 Zasloff 11/7/00 FOREIGN PATENT DOCUMENTS Foreign Patent Document Examiner Kind Code **Date of Publication** Translation Initials Number (if known) Country (MM-DD-YYYY) Yes no NON PATENT LITERATURE DOCUMENTS Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials publisher, city and/or country where published. Examiner Date Signature Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ATTORNEY'S DKT NO.	APPLICATION NO.
033053-025	09/972,425
APPLICANT	
Kenneth C. Cundy, et al.	
FILING DATE	GROUP
October 5, 2001	1614

	U.S. Patent (Document				
Examiner Initials	Number	Kind Code (if known)	Name of Patentee or Applica of Cited Document	ant	Date of Pub (MM-DD-)	
BB	4,508,728		Nagai et al.		4/2/8	35
	4,908,353	-	Yamamoto et al.		3/13/	90
	5,094,848	1	Brixner		3/10.9	92
1	5,110,797		lenaga et al.	5/5/9	2	
BB	6,051,683		Deigin et al.		4/19/20	00
					REC	T
					1120	<u>/ L</u>
					AUG :	2
					TECH CEN	TE
		F	UNITED PATENT DOCUMENTS	5	I LOIT OLIN	
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Foreign Patent	Document	Control of the Contro		and the most of the last the property was great things and the second	
Examiner Initials	Number	Kind Code (if known)	Country		ate of Publication (MM-DD-YYYY)	
	SU285929		Soviet Union		-1/13/7 1	_
Marin Landerphil (1995 Marin		neggeraalan jibaraa nii kan nii 11 filosi ka sa ka sa	PATENT LITERATURE DOCUM	* Start (Figure) Color (Figure)		4500
Examiner Initials			or (in CAPITAL LETTERS), title of the a strong, serial, symposium, catalog, etc.), publisher, city and/or country where	date, page	e(s), volume-issue nui	
Examiner	Padio		Date Considered	4/2	6703	